GLP-1 Medications Demonstrate Promise in Addiction Treatment

Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes and obesity, may also offer a novel approach to treating substance use disorders. Millions of Americans currently use these medications – including Ozempic, Wegovy, Mounjaro, and Zepbound – and ongoing research indicates a potential to expand their therapeutic applications.

Beyond Diabetes and Obesity: A New Frontier for GLP-1s

GLP-1 receptor agonists work by mimicking the effects of the GLP-1 hormone, influencing digestion, insulin regulation, and appetite control. They are known for reducing cravings and what users describe as “food noise.” Beyond their established benefits in managing diabetes and obesity, studies have demonstrated positive effects in cardiovascular disease ¹, heart failure ², sleep apnea, and kidney disease. Now, addiction treatment is being explored as a potential new application.

How GLP-1s Might Combat Addiction

Dr. W. Kyle Simmons, a professor of pharmacology and physiology at Oklahoma State University, believes that the widespread use of GLP-1s could revolutionize addiction treatment. “If these drugs turn out to be safe and efficacious for treatment of substance-use disorder, since they are so broadly used for other reasons in our society, they would just automatically, de facto, become the most widely prescribed pharmacotherapy for addiction,” he stated.

Research, primarily conducted in animal models, suggests that GLP-1s impact the brain’s reward systems. Observational studies of individuals prescribed GLP-1s for other conditions, along with anecdotal reports, have further fueled interest. Smaller clinical trials have shown promise in treating alcohol-use disorder, but larger, more definitive trials are crucial.

Recent Research Highlights Potential Benefits

A recent study published in the BMJ ³ analyzed data from over 600,000 veterans with type 2 diabetes treated with either GLP-1 medications or SGLT2 inhibitors. Researchers found that those using GLP-1 drugs were less likely to develop substance use disorders or experience adverse outcomes like hospitalization or overdose.

Dr. Ziyad Al-Aly, clinical epidemiologist and chief of the Research and Development Service at the VA St. Louis Health Care System, emphasized the surprising breadth of the effect. “We’re talking about a diabetes and obesity drug; we’re not talking about an addiction drug here,” he said. “What’s surprising is the breadth and consistency of effect across all of these different substances.” The study indicated approximately 7 fewer cases of substance use disorder per 1,000 individuals over a three-year period associated with GLP-1 use.

Impact on Specific Substances

The study examined risks associated with alcohol, cannabis, cocaine, nicotine, opioids, and other substances. Notably, GLP-1 use was linked to potential protective effects against cocaine and cannabis use disorders, conditions for which there are currently limited pharmacological treatments. The research suggested a 50% reduction in drug-related deaths among those already diagnosed with a substance use disorder.

Cautions and Considerations

While the findings are encouraging, experts urge caution. Dr. Caleb Alexander, a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, noted that the observed reduction in overdose deaths appeared “too large to be believable,” though he acknowledged the study’s strengths. He suggested that individuals initiating GLP-1 medications may be more motivated to adopt healthier behaviors and engage more actively with healthcare providers, potentially influencing outcomes independently of the drug itself.

Simmons also pointed out that the study population, drawn from VA medical records, was predominantly male and older, raising questions about the generalizability of the results.

Ongoing and Future Research

Numerous randomized controlled trials are currently underway to further investigate the efficacy of GLP-1s in addiction treatment. Simmons is leading a trial evaluating semaglutide for alcohol reduction, and the National Institute on Drug Abuse is conducting a similar study. Novo Nordisk is planning trials to assess the impact of its drugs on alcohol consumption in patients with alcohol-related liver disease, while Eli Lilly is testing brenipatide for alcohol, tobacco, and opioid use disorders.

Addressing Safety Concerns

Initial concerns about a potential link between GLP-1 medications and increased risk of suicide or suicidal ideation prompted investigations by European regulators. However, subsequent studies, including a large review of US health records, have not confirmed this association. The recent BMJ study even reported a 25% reduction in suicidal ideation among GLP-1 users.

Remaining Questions

Despite the promising results, significant questions remain. Researchers are investigating the long-term effects of GLP-1s, the potential for tolerance development, and the impact on the brain’s reward circuitry and overall enjoyment of life. Al-Aly emphasizes the demand for continued research, stating, “We don’t know what we don’t know about these drugs.”

Key Takeaways

• GLP-1 medications, originally designed for diabetes and obesity, are showing potential as a treatment for substance use disorders.
• Research suggests GLP-1s may impact the brain’s reward systems and reduce cravings.
• A recent study of veterans with diabetes found that GLP-1 use was associated with a lower risk of developing substance use disorders and a significant reduction in drug-related deaths.
• Ongoing clinical trials are crucial to confirm these findings and determine the long-term effects of GLP-1s in addiction treatment.

Disclaimer: This article provides general information and should not be considered medical advice. Consult with a healthcare professional for personalized guidance.